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Abstract
In this study, polyurethane-films loaded with diclofenac were used to analyze the
drug release kinetics and mechanisms. For this purpose, the experimental proce-
dures were developed under static and dynamic conditions with different initial
drug loads of 10, 20, and 30%. In the dynamic condition, to better simulate the
biological flow, drug release measurements were investigated at flow rates of 7.5
and 23.5 ml/s. These values indicate the flow rate of the internal carotid artery
(ICA) for a normal state of a body and for a person during the exercise, respec-
tively. The experimental data were analyzed and adjusted by Higuchi,
Korsmeyer–Peppas, First-order, zero-order, and Peppas–Sahlin models in
order to understand the mechanisms contributed. Finally, drug release mecha-
nisms were specified by investigating the model correlation coefficients.
Experimental results showed that increasing the flow rate and initial drug
loads enhance drug liberation. In addition, the rate of release is more
influenced by the drug dosage in the static state. The analysis revealed that dif-
fusion, burst, and osmotic pressure are the principal mechanisms contributed.
Moreover, Fickian type was the dominant mechanism at all duration of
release. However, it was discovered using Peppas–Sahlin model that the con-
tribution of the diffusion mechanism decreases with increasing flow rate and
initial dosage. Furthermore, the tests at different drug dosages showed that the
number of stages in medication release profile is independent of the flow rate
and the medicine percentage. One can conclude that the drug release kinetic
in static state is more influenced by drug dosage compared with dynamic state.
KEYWORD S
diffusion, dosage, drug release mechanisms, flow rate, polyurethane film
1 | INTRODUCTION
The application and improvement of drug delivery sys-
tems (DDS) in order to improve the safety and efficacy of
conventional drugs have been the focus of many studies.
Due to the importance of achieving appropriate drug
release profiles from carriers as well as having properties
such as biocompatibility, biodegradability, or nonbi-
odegradability and mechanical properties has led to the
widespread use of polymers.1,2
DDS in the form of the polymeric matrix have drawn
interest in the area of therapeutic. Hydrophilic polymers
are in this choice because they are generated with pore
spaces which facilitate the release of the drug, especially
as for low aqueous soluble drugs. In this regard, chemical
and physical properties of the polymer such as glass tran-
sition temperature, permeability, viscosity, degradability,
and concentration of polymers are the influential criteria
that control the drug release from the polymer carrier.3
Thus, all the characteristics referring to the polymer and
drug, take account in the drug release profile.4 Drug
release refers to the definition where the drug solutes/
nonsolutes migrate from the initial position of the carrier
to the outer side of the carrier to contact with the
medium and consequently release in the medium.4 Stud-
ies focused on achieving the systems with reducing toxic-
ity, side effects, and enhancing the effectiveness of
treatment-controlled release. Controlled drug release is
affected by some parameters to improve the therapy's effi-
cacy. These include, for example, the released time rate,
global time, and position accuracy.5
DDS in the form of the polymeric matrix have drawn
interest in the area of therapeutic. Hydrophilic polymers are
in this choice because they are generated with pore spaces
which facilitate the release of the drug, especially as regards
for low water soluble drugs. The time that the polymer is
contacted with the aqueous medium diverse phenomena can
occur like, degradation, dissolution, swelling, etc..6 This can
result in different drug release profiles by the mechanisms of
diffusion, convection, burst, ion exchange, osmotic pressure,
etc. Depending on the necessities of the therapy, each of
these mechanisms can take importance to the others.7
The effects of the presence of each mechanism can
differ depending on the polymer properties. As an exam-
ple, the water swollen and nonswollen polymers have
been compared.8,9 It was revealed that the diffusion of
the drug in the water swollen polymer was increased
compared with the nonswollen polymer due to the crea-
tion of the free volume fraction. However, it is not always
the same, as another study indicated that swelling of the
nondegradable polymer decreases the release rate. This is
for the reason that, it increases the path of the drug in
the matrix for attaining to the release medium.8,9
Polyurethane has always been used in biomedical appli-
cations due to the good biocompatibility and mechanical
properties.4,10–15 Polyurethane due to show the favorable abil-
ity to drug release profiles in various modes such as micro-
particles, films, and also as a coating on implants and stents
has been the focus of many studies. In some studies, it is
noted that the release from the nondegradable polymeric sys-
tem is controlled by diffusion. In this case, the parameters
which are taken importance are the thickness and hydrophi-
licity of the polymeric matrix; on the other hand, the solubil-
ity of the drug charged in the polymer also takes value.
However, in a study by Huynh et al.16 they have studied the
release behavior of the chlorhexidine diacetate from the
nondegradable PU and found that the release was followed
by zero order mechanism. In the case of diffusion-controlled
mechanisms, the reservoir and matrix type of the DDS is in
the main categories. Indeed, matrix type is more favorable as
it accepts not the risk of depleting the drug by the tearing of
the cover layer. Furthermore, it utilizes a straightforward pro-
cess of fabrication.17–19
The other parameters which are important in the release
are related to the properties of the drug. One of the types of
the drugs used in the case of cardiovascular stenting is the
antiinflammatory drugs. Diclofenac is one of the most pre-
scribed nonsteroidal antiinflammatory drugs which inhibits
the pain and reduces the inflammation.20–22 Where different
indicators such as the solubility, particle size, hydrophilicity of
drug, etc., will affect the release profile.23–25 The drug particles
in the matrix can have two kinds: they can dissolve in the
polymer solvent therefore covalent bonds with the polymer
are made or they can be dispersed in the matrix in the particle
shape. The first type of degradation of the polymer affects the
drug release data. However, for the second case degradation
rate of the polymer, drug loading, solute size, swelling, and sol-
ubility influence the release rate.9
Consequently, according to the polymer and the drug
is chosen, various mechanisms of release can contribute to
the release of the drug from the DDS. These mechanisms
can continue the dissolution of the drug and DDS, diffu-
sion of the liquid into the DDS and diffusion of the drug
from DDS to the release medium, swelling, degradation,
erosion of the DDS, osmotic pressure, etc..26 Depending on
the portion of participation, each of these mechanisms can
represent the dominated mechanism of release or can be
negligible. Also, depending on the rate of each mechanism
occurring during the time of the release, it can be rate con-
trolling on the whole period of the release.27
In this study, the results related to the experiments con-
ducted with charged polyurethane (PU) have been demon-
strated. The experiments have been performed with varying
two parameters: (a) flow rates of 0, 7.5, and 23.5 ml/s where
there is a lack of study on it and, (b) drug percentages of
10, 20, and 30 wt%. Then the steps related to the whole release
were identified and the mechanisms have been analyzed. Sub-
sequently, the contribution of the identified mechanisms has
been calculated. The flow rate and drug ratio caused a signifi-
cant effect on the mechanism of drug release from the carrier.
2 | EXPERIMENTAL PROCEDURE
2.1 | Materials
2.1.1 | Polyurethane
In this analysis the substance used is nondegradable poly-
urethane (PU) which is the result of the synthesis of the
hardener (isocyanate type 4,4-diphenylmethylene
diisocyanate [MDI]) with resin Gyrothane 639 which is
composed of polyol with IOH value of 336 (mg KOH/g),
dye, and catalyst. The substance prepared from the
hardener-resin combination in a proportion of 2:5
according to the datasheet, casted in a mold, and heated
at 50C for about 30 min. The related items were supplied
from the RAIGI Company.
2.1.2 | Diclofenac
Diclofenac as a nonsteroidal antiinflammatory drug is
the agent loaded in PU samples for drug release tests.14 It
was purchased from Genevrier Laboratory in granular
shape with a density of approximately 450.7 mg/ml. The
solubility of the drug at a temperature of 37C in water is
about 5.554 g/L. The particle size was determined by
SEM images: around 40 μm ≤ particle size ≤ 160 μm.
2.2 | Preparation of carriers and drug
loading
For drug release experiments, polymer films with the
dimensions of 30 × 5 × 2 mm3 were prepared. This
dimension is considered an enlarged dimension of the
strut of a stent. A process of molding and heating in an
oven at the temperature of the 50C for about 30 min was
performed. For the samples with the active substance in
the initial preparation of the mixture, a certain dosage of
the drug [the mass ratio of drug/(drug + polymer): 10,
20, and 30 wt%] was added to the resin. After homoge-
neously dispersing the drug in the polyol the hardener
was added to the mix. Finally, the prepared mix was
poured in the mold and then it was put in the oven. Drug
particles were maintained in the form of the granules
after mixing. Figure 1 shows the schematic of this proce-
dure. Scanning electronic microscope “HITACHI 4800
SEM” has been used to analyze the morphology of the
microstructure of the specimen throughout the study.
2.3 | Test bench components
The test facility used in this experiment is represented in
Figure 2. This equipment was designed to perform the
test from static flow to the different flow rates by the aid
of a pump and inverter. Valves are for adjusting the flow
rate. A tank with the capacity of 10 L is employed,
although to avoid the risk of saturation of liquid, each
2 days of test it was refreshed with new one.
3 | EXPERIMENTAL RESULTS
AND DISCUSSIONS
3.1 | Drug release procedure and
associated measurements
Measurement methods were performed according to the
following method. In the first step, the samples were
dried in the oven at 50C for 1 hr to remove any mois-
ture. The samples were weighed immediately after
FIGURE 1 Process of casting
for preparing PU films with the
diclofenac dispersed inside [Color
figure can be viewed at
wileyonlinelibrary.com]
cooling in the desiccator (m0). The second step is to put
the samples in the in-vitro test. Further, the samples are
collected from the test after a specified period for each
test, to begin the following stage. The third step com-
prises cleaning the surface of the taken samples with a
dry cloth to remove any water present. These samples
then weighed (m1). After that, to remove all the water in
the film, the samples were transferred to an oven at 50C,
after ensuring that all the water absorbed by the film was
removed (after the sample weight was stabilized), and the
film was weighed (m2). The equations for measuring the
water absorption and drug release are listed below:
Water absorption %ð Þ= m1−m2
m0
× 100 ð1Þ
Drug release %ð Þ= m0−m2
initial mass of drug
× 100 ð2Þ
where, m0 represents the sample mass at the initial
state; m1 is the mass after wiping; and m2 is the mass
after drying in the oven.
3.2 | Water absorption at diverse flow
rates and drug percentages
Figure 3(a) shows the water absorption of the PU loaded
with diverse drug percentages of 0, 10, 20, and 30% at the
static state. It is noted that the water penetrates to the
PU.0.Q:0 (PU with zero percentage of the drug at the flow
rate of zero ml/s) up to 5%, where it is augmented to the
70% for the samples with 30% of the drug after 10 days of
immersion.
Therefore, the presence of the hydrophilic drug
carries out a significant role in water absorption. It is
remarkable that the values of the percentage of water
absorption are affected as well by the variation of the
density of water and diclofenac which are 997 and
450.7 mg/L, respectively.
Figure 3(b) shows the results of the water absorption
for three various percentages of the drug at the flow rate
of 7.5 ml/s; the concept is repeating once more for the
effect of the drug percentage on water absorption in the
flow condition. This figure indicates that the water
absorption is increased by increasing the drug percentage.
By comparing the three curves of the Figure 3(a)–(c),
one can note that the equilibrium water absorption for
the samples with the same percentage of drug (e.g., 10%)
at different flow rates gives rather the same value
(30%). Therefore, the equilibration value of water
absorption is independent of the flow rate, and it firmly
depends on the composition of the sample (the percent-
age of the drug loaded). Further, it will affect the release
behavior, whereas all the mechanisms mentioned attrib-
uting to the release are highly related to the water/liquid
absorption. In the case of the more drug percentage due
to the more quantity and larger diameter of the pores,
FIGURE 2 Equipment elements for tests at different flow rates
water absorption increases where the free volume in the
matrix can handle more solvent molecules. This process
goes on until reaching an equilibrium value. Applying
the equation of Korsemeyer–Peppas for the water absorp-
tion results gives the n value lower than 0.5. Therefore, it
indicates that water absorption and hence swelling in all
the experimental tests are controlled by the diffusion
mechanism (Fickian diffusion).28–30
3.3 | Cumulative drug release at diverse
flow rates and drug percentages
Figure 4(a),(b) shows the drug release percentage for the
three loaded PU cases in the case of static and dynamic
with the flow rate of 7.5 ml/s.
Results are given in Figure 4(a),(b), depict the drug
release at 10, 20, and 30% of initial dosage under static and
dynamic conditions, respectively. It is clear that the release
time for the samples with the higher drug dosage has
decreased. On the other hand, by comparing Figure 4(a)–
(c) one can note that with increasing flow rate, drug
release is occurring at a higher rate. However, these results
need more analysis, which is discussed in Section 5.
3.4 | Understanding of drug release
mechanisms: Strategy to investigate
Mathematical models have always been one of the most
effective ways to improve the design of different carriers
for the DDS. In addition, it has always been important to
determine the mechanisms of drug release and release
kinetics for various systems.31–34 For this purpose, in this
section, we will investigate the steps of drug release from
the carrier as well as the precise mechanisms of drug
release from the carrier using fitting experimental data
with different physical models.7,10,14,35,36 Additionally, all
the regressions were performed with 95% confidence
intervals.
FIGURE 3 Water absorption percentage in accordance to the time of the incubation for different percentages of the drug at (a) static
state, (b) the flow rate of 7.5 ml/s, and (c) 23.5 ml/s [in PU.X.Q:Y:X is indicator of drug percentage and y is indicator of flow rate (ml/s)]
[Color figure can be viewed at wileyonlinelibrary.com]
In order to investigate the mechanisms, first finding
the steps of the release profile is considered. The experi-
mental data was investigated using Higuchi model,
which has been used extensively in several studies to
evaluate the stages of drug release from carries.27,37–39






where, Q is the amount of drug released at time t per
unit area, C is the amount of primary drug in the matrix
per unit volume, Cs is the drug solubility in the matrix
media, and D is the diffusion coefficient of the drug mole-
cules in the carrier. In general, the simplified Higuchi







where, Mt and M∞, are drug released at t and infini-
tive time, respectively, and KH is a kinetic constant.
After identifying the steps, Korsmeyer–Peppas was
applied to each curve in order to detect the mechanisms
whether it is diffusion or degradation and swelling con-





where, k is a constant and the exponent n determines
the mechanism of drug release from the carrier.
As per to the coefficient of categorization for a thin
film, when n < 0.5, the semi-Fickian mechanism is pres-
ented while the n = 0.5 the drug release mechanism can
be controlled by Fickian diffusion. Whereas 0.5 < n < 1
the mechanism can be followed by anomalous transport
(diffusion and degradation: non-Fickian). Once n = 1 the
release can be controlled by degradation.
FIGURE 4 Cumulative drug release in accordance with the time of the incubation for different percentages of the drug and at (a) static
state, (b) the flow rates of 7.5 ml/s, and (c) 23.5 ml/s [Color figure can be viewed at wileyonlinelibrary.com]
To further investigate the mechanism of drug release
from carriers; Zero-order, First-order, and Peppas–Sahlin
models were examined. Zero-order model is utilized




Here, model order is the order of release rate and not
the order of cumulative release.
The first-order release in the case where drug release
experiences an exponential behavior, also, the dissolution




=1−exp −ktð Þ ð7Þ
In Peppas–Sahlin equation, drug release is controlled
by the diffusion and relaxation mechanism43:
Mt
M∞
= k1tm + k2t2m ð8Þ
where, k1 and k2 are kinetic constants and m is the
diffusion exponent.
Moreover, Peppas–Sahlin model is used to calculate
the percentage of the contribution of the mechanism of
the diffusion during the release. In Peppas–Sahlin equa-






where, k1 and k2 are constants obtained from Equa-
tion (6), the contribution of the diffusion mechanism at
different times can be investigated.
Figure 5 shows the algorithm for following this
strategy.
3.5 | Identification of drug release steps:
Higuchi equation
The experimental results have been analyzed by Higuchi
equation (Figure 6 and Table 1). Fitting the experimental
data at the static and dynamic conditions with different
dosages by Higuchi model, presented two-step drug
release from the PU films.
The regression results of the Higuchi model for each
step are presented in Table 1. The correlation coefficients
for all the samples were high and near to 0.99. In general,
comparing the values of the KH from Table 1, show that
the kinetic constants in the first and second steps are
increased by flow rate.
From these curves, the below conclusion can be drawn:
• The number of steps seems to be independent of the
considered parameters.
• Second step gives another kinetic of the release more
than the first step. Therefore, it notes the presence of
the other mechanism(s) or it can be the same mecha-
nism as first step but with different kinetics due to
some reasons.
• The release kinetics of the first step is independent of
different drug percentages for different flow rates.
• One can define that the threshold time, which is the
time where the kinetic changes, are different for
dynamic flow rates; however, it is the same for the
static state shown in Figure 7(a).
• In static state, the rate of drug release in the second
step increases by increasing the drug dosage. However,
it is constant for dynamic flow rates (Figure 7(b)). On
the other hand, the rate of release is more influenced
by the drug dosage in the static state.
• For dynamic flow rates, it is notable that by increasing
the drug percentage the threshold time is increased
(Figure 7(a)). The later confirms that when the drug
content is increased at dynamic state more particles
can participate in the release at first step. This means
there is a delay time in kinetic reduction by increasing
the drug dosage perhaps due to the presence of flow or
agitation.
3.6 | Investigation of the drug release
mechanism
In the previous section, dual-stage drug release from
films was observed. In this section, the mechanisms of
drug release under static and dynamic conditions were
investigated.
3.6.1 | Static state
In this section, the mechanism of drug release at the dif-
ferent dosages of Diclofenac from PU.10.Q:0, PU.20.Q:0,
and PU.30.Q:0 is studied. To investigate and intuition the
mechanisms of drug release from carriers, Equations (5)–
(7) were fitted. The fittings were applied to each step; the
results of these models are presented in Table 2. Figure 8
shows the curves related to the fitting of the
Korsemeyer–Peppas model.
The constants related to the fitting of Equations (5)–(7)
related to Korsemeyer–Peppas, Zero-order, and First-order
models, respectively, are presented in Table 2. The unfavor-
able fit of Equations (6) and (7) indicates the ignorable of
polymer degradation and nonintegration of the dissolution,
respectively. The regression results of the Korsemeyer–
Peppas model presented in Table 2 show the correlation
coefficients for all three samples were higher than 0.98. The
n values are less than 0.5. It is noteworthy that, the amount
of n value less than 0.5 indicates the pseudo-Fickian mecha-
nism44,45 for drug release from the loaded PU. Therefore, in
the case of the static state at two steps for three different
percentages diffusion is the involved mechanism but it is
not the only mechanism intervene.
3.6.2 | Dynamic state
For identifying the mechanisms in dynamic state, the
flow rate of 7.5 ml/s was chosen. The results of regression
by Equations (5)–(7) on the data are presented in Table 3,
and as per the obtained value, it can be stated that the
mechanism of drug release represents pseudo-diffusion.
Like as the static one here also the curves do not show
good fit to the Equations (6) and (7); therefore, it
indicates that the release is unintegrated into the dissolu-
tion or degradation of the matrix. The semi-Fickian
mechanism is controlling the drug release at all two
steps. However, for considering the degradation in the
test situation degradation test were conducted in the con-
tinuous flow state where, the three pure polyurethane
samples were immersed in the aquatic environment for
28 days. The results demonstrated no mass loss during
this test. As the mass loss is an indicator of the degrada-
tion, the material is facing the first type of degradation
where it experiences a decrease in mechanical properties
but no weight loss during the test period.40,41 Therefore,
referring to the experimental degradation test of polyure-
thane samples, no degradation was observed. Figure 9
shows the curves related to the fitting of Korsemeyer–
Peppas model applied on these results.
3.7 | Contribution of the diffusion
mechanism
3.7.1 | Effect of flow rates
After confirming the diffusion transport of the drug from
the carriers, the contribution of diffusion mechanisms for
FIGURE 5 Algorithm for defining the mechanisms contributed during the release from a drug loaded carrier
the samples with 10% of drug at the flow rates of 0, 7.5,
and 23.5 ml/s by Equations (8) and (9) was calculated.
Figure 10 shows the contribution of the diffusion mecha-
nism against drug release times for PU.10.Q:0, PU.10.
Q:7.5, and PU.10.Q:23.5. It shows that the portion of the
diffusion mechanism decreased along with increasing the
time for all three samples and also it is clear that an
increase of flow rate from 0, 7.5 to 23.5 ml/s, causes a
decrease in the portion of the diffusion mechanism in
drug release.
The decrease in the contribution of the diffusion
mechanism over time will be justified by the decrease in
the concentration gradient by the time because the diffu-
sion mechanism is controlled by the potential chemical
gradient. As mentioned, drug release can involve a vari-
ety of mechanisms, common mechanism for drug deliv-
ery based on polyurethanes can be diffusion.37 In the
previous section, the contribution of the diffusion mecha-
nism was obtained by Equation (9) and it was shown that
the diffusion mechanism was the dominant mechanism
throughout the drug release period, but according to
Figure 10, all the drugs were not released just by this
mechanism. It is also noteworthy that if the mechanism
of drug release was uniquely based on diffusion, the n
FIGURE 6 Step analyzing by Higuchi model for the experimental tests of drug release with different drug loads (10, 20, and 30%) at
flow rates of (a) 0, (b) 7.5 ml/s, and (c) 23.5 ml/s [Color figure can be viewed at wileyonlinelibrary.com]





Step 1 Step 2 Step 1 Step 2
PU.10.Q:0 0.108 0.037 0.98 0.99
PU.20.Q:0 0.108 0.049 0.98 0.99
PU.30.Q:0 0.108 0.064 0.99 0.98
PU.10.Q:7.5 0.175 0.071 0.98 0.99
PU.20.Q:7.5 0.175 0.071 0.98 0.98
PU.30.Q:7.5 0.175 0.071 0.97 0.98
PU.10.Q:23.5 0.285 0.106 0.98 0.99
PU.20.Q:23.5 0.285 0.106 0.98 0.99
value obtained from Equation (5) should be equal to the
m value obtained from Equation (8)43 which in accor-
dance with the calculations these values were not equal.
Therefore, the contribution of the other mechanisms
takes attention. The contribution of the other mecha-
nisms can be calculated by the following relation:
Total drug release = (diffusion mechanism + other
mechanisms) contributions to release.
The results of the degradation of polyurethane at dif-
ferent times showed no degradation. Therefore, drug
release cannot be attributed to the carrier's degradation
or dissolution.
In the first step for the matrix carrier especially with
the undissolved drug particles, the first moments of the
release are probably related to the phenomena of burst
release. As the studies of the burst-release have shown
this mechanism inevitably occurs in the first liberation
period and will continue until the release of the drug is
stable.46,47 Referring to the initial values of the burst
release obtained from the Figure 10 indicate that the
burst release is increased by changing the state of the
flow from static to continuous, whereas it shows fewer
differences for two cases of flow rates.
For the second step, another mechanism in which the
drug can be released is based on osmotic pump, this
mechanism can be created by osmotic pressure and it is
FIGURE 7 Comparing (a) the threshold times and (b) KH (release kinetic) for the second step of drug release; at different drug
percentage for two flow rates of zero and 7.5 ml/s [Color figure can be viewed at wileyonlinelibrary.com]

































PU.10.Q:0 0.19 0.23 0.29 0.25 0.99 0.99 0.042 0.002 0.12 0.95 0.063 0.015 0.29 0.78
PU.20.Q:0 0.16 0.51 0.30 0.18 0.98 0.99 0.042 0.002 0.12 0.95 0.062 0.022 0.25 0.87
PU.30.Q:0 0.21 0.60 0.31 0.16 0.99 0.98 0.046 0.002 0.19 0.91 0.072 0.029 0.57 0.93
FIGURE 8 Regression results of PU.10.Q:0, PU.20.Q:0, and
PU.30.Q:0 in two steps with Korsemeyer–Peppas model [Color
figure can be viewed at wileyonlinelibrary.com]
not based on diffusion. One of the reasons for this mecha-
nism is the absorption of water into the polymer. Also,
the polymer degradation must be negligible and the
channels of the polymer should be larger than
60 microns.48–50 This value is justified by the microscopic
images (Figure 11). In this figure the dark round holes
refer to the cavities, where the lighter holes refer to the
bubbles created during the preparation which may con-
tain the drug inside of them.
The results of water absorption showed the amount of
water absorbed by PU.10.Q:0, PU.10.Q:7.5 and PU.10.
Q:23.5 increased with time. Moreover, increasing the
flow rate increases water penetration into the polymer
channels and pores. On the other hand, the osmotic
pumping is based on the osmotic pressure resulting from
water absorption and the solutes dissolved in it.47,50
Depending on the type of the matrix as it is semiperme-
able or nonpermeable with the solutes inside, the osmotic
pressure can result in the swelling or shrinkage of the
samples, respectively. According to the semipermeable
samples used in this study swelling is the probable case.
However, as it is mentioned in the Section 3.2 the swell-
ing in this case is also Fickian-controlled. Thus, it can be
said that increasing the rate of water uptake over time
and increasing the flow rate causes the release of the
drug through osmotic pressure.48,50 Consequently, the
contribution of the diffusion mechanism to the drug
release is decreased by increasing the flow rate and the
time of the incubation.
3.7.2 | Different drug percentages
Figure 12 shows the contribution of diffusion mecha-
nisms for the samples with different drug percentages at
the flow rate of 7.5 ml/s by Equations (8) and (9). As
shown in Figure 12, the contribution of the diffusion
mechanism decreases over time for all three cases. Fur-
thermore, the nonequilibrium coefficients n and m

































PU.10.Q:7.5 0.28 0.08 0.27 0.46 1 1 0.11 0.005 0.28 0.98 0.17 0.05 0.59 0.71
PU.20.Q:7.5 0.29 1.11 0.28 0.12 1 0.99 0.113 0.006 0.40 0.93 0.18 0.07 0.64 0.84
PU.30.Q:7.5 0.35 4.16 0.24 0.04 0.99 1 0.13 0.007 0.11 0.93 0.22 0.88 0.71 0.84
FIGURE 9 Regression results of PU.10, 20, 30.Q:7.5 with
Korsemeyer–Peppas model [Color figure can be viewed at
wileyonlinelibrary.com]
FIGURE 10 Contribution of diffusion in accordance with the
time of the release at different flow rates for PU + 10% drug [Color
figure can be viewed at wileyonlinelibrary.com]
obtained from equations Korsemeyer–Peppas and
Peppas–Sahlin showed that drug release was not affected
only by diffusion. In the previous section, it was shown
that the amount of water absorbed by the carrier
increased over time. On the other hand, with increasing
drug content in polymer films, water absorption
increased which reduced the influence of the diffusion
mechanism on drug release and increased the contribu-
tion of the other mechanisms.
Referring to the Figure 12 at the first step as the con-
tribution of the diffusion is decreased at the starting point
of release for the samples with 10, 20, and 30% of drug.
Therefore, release related to the contribution of other
phenomena at the first period of the release, respectively,
for 10, 20, and 30% of drug increases. As mentioned
above for the matrix sample at the first moments of the
release the probable phenomenon is the burst release
which is less related to the water absorption. As the per-
centage of the drug increases the probability of the drug
particles to stay on the surface of the polymer matrix
increases. It is, therefore, by increasing the drug percent-
age the value related to the burst release increases.
In the second step, the other mechanism which is
contributed is the osmotic pressure49,50 which is
increased by the water absorption and increasing the free
space by releasing the more drugs. It is notable more the
drug percentage, more the contribution of the osmotic
pressure. The system is more nonequilibrium where the
drug percentage increases, therefore activation energy for
contributing osmotic pump increases. Moreover, hydro-
philicity of the sample due to the more hydrophilic drug
increases, hence water absorption increases, and vapor
pressure would be another reason for commencing the
osmotic pressure. Additionally, another parameter affect-
ing the osmotic pressure is the permeability of the matrix,
where increasing the drug content increases the perme-
ability in the matrix. Therefore, the release of the drug
through osmotic pressure will depend on the amount of
drug loaded and consequently water absorbed into the
polymer.
4 | CONCLUSION
In this work, the release of diclofenac from a polyure-
thane film loaded with various drug percentages was
studied under static and dynamic flow conditions. Water
absorption and cumulative drug release values were iden-
tified for all flow rates and drug dosages.
The experimental data was investigated using Higuchi
model and proposed calculation algorithm to evaluate
the stages of drug release from carries and contributed
mechanisms. Drug release took place in two stages for
static and dynamic states which were independent of the
considered parameters. The second step gives another
kinetic of the release more than the first step. Therefore,
it notes the presence of the other mechanism(s), or it can
be the same mechanism as the first step but with differ-
ent kinetics due to some reasons. One can notice that the
FIGURE 11 Microscopic
images representing the size of the
holes (PU.10.Q:7.5, 1 hr after the
test) [Color figure can be viewed at
wileyonlinelibrary.com]
FIGURE 12 Contribution of diffusion in accordance with the
time of the release at different initial drug percentages at the
Q = 7.5 ml/s [Color figure can be viewed at wileyonlinelibrary.com]
release kinetics of the first step was independent of differ-
ent drug percentages for different flow rates. Threshold
time, which is the time where the kinetic changes, are
different for dynamic flow rates; however, it is the same
for the static. In addition, the rate of release is more
influenced by the drug dosage in the static state. There
was a delay time in kinetic reduction by increasing the
drug dosage perhaps due to presence of flow or agitation.
The results allowed the identification of three drug
delivery of mechanisms; burst-release, diffusion, and
osmotic pressure mechanisms. The diffusion represents
the dominant mechanism in all periods of delivery. How-
ever, the contribution of the burst-release throughout the
initial time and the osmotic pressure during the second
step is accompanied by the diffusion. The proportion of
drugs delivered in accordance with time for each of these
mechanisms changes during the release period. In addi-
tion, the contribution of the other mechanisms apart
from diffusion increases with the flow rate and as the
percentage of drugs.
CONFLICT OF INTEREST





[1] G. Tiwari, R. Tiwari, B. Sriwastawa, L. Bhati, S. Pandey,
P. Pandey, S.K. Bannerjee, Int. J. Pharma. Investig. 2012,
2, 2.
[2] W. B. Liechty, D. R. Kryscio, B. V. Slaughter, N. A. Peppas,
Annu. Rev. Chem. Biomol. Eng. 2010, 1, 149.
[3] T. K. Dash, V. B. Konkimalla, J. Controlled Release 2012,
158, 15.
[4] T. J. Johnson, K. M. Gupta, J. Fabian, T. H. Albright, P. F.
Kiser, Eur. J. Pharm. Sci. 2010, 39, 203.
[5] F. R. Nezami, L. S. Athanasiou, E. R. Edelman, in Biomechan-
ics of Coronary Atherosclerotic Plaque, Academic Press, Lon-
don 2020, p. 611.
[6] C. Bode, H. Kranz, A. Fivez, F. Siepmann, J. Siepmann,
J. Controlled Release 2019, 306, 97.
[7] Y. Fu, W. J. Kao, Expert Opin. Drug Deliv. 2010, 7, 429.
[8] Q. Guo, P. T. Knight, P. T. Mather, J. Controlled Release 2009,
137, 224.
[9] J. Y. Cherng, T. Y. Hou, M. F. Shih, H. Talsma, W. E.
Hennink, Int. J. Pharm. 2013, 450, 145.
[10] D. Y. Arifin, L. Y. Lee, C.-H. Wang, Adv. Drug Deliv. Rev. 2006,
58, 1274.
[11] M. D. Campiñez, E. Benito, L. Romero-Azogil, A. Aguilar-de-
Leyva, M. G. García-Martín, J. A. Galbis, I. Caraballo, Eur.
J. Pharm. Sci. 2017, 100, 285.
[12] A. Basu, S. Farah, K. Kunduru, S. Doppalapudi, W. Khan, A.
Domb, 8-Polyurethanes for controlled drug delivery, in
Advances in Polyurethane Biomaterials, MA: Woodhead Pub-
lishing, Cambridge 2016, p. 217.
[13] M. B. Lowinger, S. E. Barrett, F. Zhang, R. O. Williams, Phar-
maceutics 2018, 10, 55.
[14] S. A. Fouad, E. B. Basalious, M. A. El-Nabarawi, S. A. Tayel,
Int. J. Pharm. 2013, 453, 569.
[15] N. Abbasnezhad, M. Shirinbayan, A. Tcharkhtchi, F. Bakir,
J. Drug Deliv. Sci. Technol. 2020, 55, 101500.
[16] T. T. N. Huynh, K. Padois, F. Sonvico, A. Rossi, F. Zani, F.
Pirot, J. Doury, F. Falson, Eur. J. Pharm. Biopharm. 2010,
74, 255.
[17] H. Patel, D. R. Panchal, U. Patel, T. Brahmbhatt, M. Suthar,
J. Pharm. Sci. Biosci. Res. 2011, 1, 143.
[18] W.-W. Yang, E. Pierstorff, J. Lab. Autom. 2012, 17, 50.
[19] A. Raval, J. Parikh, C. Engineer, Brazil. J. Chem. Eng. 2010,
27, 211.
[20] L. Lamoudi, J. C. Chaumeil, K. Daoud, J. Drug Deliv. Sci.
Technol. 2016, 31, 93.
[21] D. Ailincai, G. Gavril, L. Marin, Mater. Sci. Eng., C 2020, 107,
110316.
[22] B. Petersen, S. Rovati, Clin. Drug Investig. 2009, 29, 1.
[23] S. McGinty, G. Pontrelli, J. Controlled Release 2015, 217, 327.
[24] H. Gasmi, F. Siepmann, M. C. Hamoudi, F. Danede, J. Verin,
J. F. Willart, J. Siepmann, Int. J. Pharm. 2016, 514, 189.
[25] F. Farahmandghavi, M. Imani, F. Hajiesmaeelian, J. Drug
Deliv. Sci. Technol. 2019, 49, 132.
[26] K. Škrlová, K. Malachová, A. Muñoz-Bonilla, D. Měřinská, Z.
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